Jubilant HollisterStier

Transformations in Drug Development for Cell and Gene Therapies

The company has plans to invest $23 billion during the next five years to expand manufacturing and R&D in the US, which will include seven new facilities.

Siemens Acquires Dotmatics, Extending AI Software Portfolio into Life Sciences

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com

April 9th 2025

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

Siemens said spending on AI software is predicted to double by the end of the 2020s, in a market increasingly driven by structural shifts that underscore a need for digital transformation.

Agentic AI Growth Predicted, but More Than Half of Pharma Still Resisting Change: Report

Navigating the Complexities of Emerging Therapy Development

Lack of skills in the AI realm was a distant second among those surveyed about the biggest barrier to innovation while using the technology.

Blue Paper Boat Leading A Fleet Of Small White Boats With Compass Icon On Grey Concrete - Leadership Concept | Image Credit: ©Philip Steury -stock.adobe.com

Cynthia A. Challener

Novartis to Expand US-Based R&D and Manufacturing

Advancement of emerging therapies faces hurdles across all aspects and phases of drug development and manufacturing.

Related Content

Susan Haigney

April 11th 2025

Transformations in Drug Development for Cell and Gene Therapies

The company has plans to invest $23 billion during the next five years to expand manufacturing and R&D in the US, which will include seven new facilities.

Siemens Acquires Dotmatics, Extending AI Software Portfolio into Life Sciences

April 9th 2025

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

Siemens said spending on AI software is predicted to double by the end of the 2020s, in a market increasingly driven by structural shifts that underscore a need for digital transformation.

Agentic AI Growth Predicted, but More Than Half of Pharma Still Resisting Change: Report

Navigating the Complexities of Emerging Therapy Development

Lack of skills in the AI realm was a distant second among those surveyed about the biggest barrier to innovation while using the technology.

Cynthia A. Challener